Latest Harvard Bioscience (HBIO) Headlines
Harvard Bioscience Names Ronald Aplin to Vice President Global Operations and Quality
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately. This is a newly created position.
Nasdaq stocks posting largest volume increases
AP - Mon Mar 03, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Harvard Bioscience Reports Fourth Quarter and Year-End 2013 Results
GlobeNewswire - Thu Feb 27, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of specialized products to advance life science research, today reported financial highlights for the fourth quarter and full year ended December 31, 2013.
Harvard Bioscience Schedules Fourth Quarter and Year-End 2013 Conference Call for February 27, 2014 at 11:00 AM ET
GlobeNewswire - Fri Feb 14, 6:30AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, will announce results for its fourth quarter and year ended December 31, 2013 before market trading hours on Thursday, February 27, 2014. A conference call to discuss the company's fourth quarter and year-end financial results is scheduled for that same day at 11:00 AM ET.
Harvard Bioscience Realigns Global Operations to Create Organizational Efficiencies and Better Position It for Growth
GlobeNewswire - Wed Dec 04, 6:00AM CST
-Reallocating Resources to Higher-Growth Areas-
Upgrade Alert for Harvard Bioscience (HBIO)
Comtex SmarTrend(R) - Wed Nov 27, 7:04AM CST
Harvard Bioscience (NASDAQ:HBIO) was upgraded from Neutral to Buy at Sidoti today. The stock closed yesterday at $4.47 on volume of 393,000 shares, above average daily volume of 202,000. In the past 52 weeks, Harvard Bioscience share prices have been bracketed by a low of $3.45 and a high of $6.26 and closed yesterday at $4.47, 30% above that low price. The 200-day and 50-day moving averages have moved 0.29% lower and 1.21% lower over the past week, respectively.
Harvard Bioscience Announces Inducement Grants to Recently Hired Executives
GlobeNewswire - Mon Nov 18, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has granted the inducement stock option grants it was obligated to grant to its recently hired executives as follows:
Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology
GlobeNewswire - Wed Nov 13, 10:29AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, announced the allocation of tax basis resulting from the tax-free spin-off of Harvard Apparatus Regenerative Technology, Inc. Based on the relative fair market values of the respective companies on November 1, 2013, the first day of trading after distribution, 23.63 percent of a stockholder`s pre-distribution tax basis in Harvard Bioscience common stock should be allocated to the shares of common stock in Harvard Apparatus Regenerative Technology received pursuant to the distribution described in the Information Statement of Harvard Apparatus Regenerative Technology dated October 17, 2013.
Kellogg and BlackBerry are big market movers
AP - Mon Nov 04, 3:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Harvard Bioscience completes HART unit spinoff
AP - Mon Nov 04, 9:49AM CST
NEW YORK (AP) — Medical instruments maker Harvard Bioscience said Monday the spinoff of its Harvard Apparatus Regenerative Technology unit is complete.
Jeffrey A. Duchemin Appointed to Additional Roles of President and Director of Harvard Bioscience
GlobeNewswire - Mon Nov 04, 6:15AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that its Chief Executive Officer, Jeffrey A. Duchemin, has been appointed by the Board of Directors to the additional positions of President and Director, effective immediately. He replaces David Green, who has become President at Harvard Apparatus Regenerative Technology, Inc. (HART), which was spun off from HBIO on November 1, 2013. Mr. Green will remain on the Board of Directors of Harvard Bioscience.
Harvard Bioscience Becomes Pure-Play Developer, Manufacturer and Marketer of Tools for Life Science Research
GlobeNewswire - Mon Nov 04, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO) became a pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research on November 1, 2013. This development resulted as the previously announced spin-off of its former wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, or HART, was completed as of 12:01 a.m. on November 1, 2013.
Harvard Bioscience Reports Third Quarter 2013 Results
GlobeNewswire - Thu Oct 31, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and nine months ended September 30, 2013.
Harvard Bioscience Appoints Yong Sun as VP Strategic Marketing and Business Development
GlobeNewswire - Mon Oct 28, 6:00AM CDT
Nearly 20 Years Marketing Experience to Bolster Company's Future Expansion Into Asia and Emerging Markets
Five-Year Follow-Up of World's First Regenerated Trachea Transplant Published in The Lancet
GlobeNewswire - Wed Oct 23, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) and Harvard Apparatus Regenerative Technology (Nasdaq:HARTV) jointly announce that five years after a 30-year-old woman was implanted with the world's first tissue-engineered trachea grown in a bioreactor she lives complication-free, according to an article published October 23 in The Lancet.
Harvard Bioscience, Inc. Schedules Third Quarter 2013 Conference Call for October 31, 2013 at 11:00 AM ET
GlobeNewswire - Tue Oct 22, 2:40PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, will announce results for its third quarter ended September 30, 2013 before market trading hours on Thursday, October 31, 2013. A conference call to discuss the company's third quarter financial results is scheduled for that same day at 11:00 AM ET.
Harvard Bioscience Inc elects Yoav Sibony as VP its Global Sales
M2 - Mon Oct 21, 7:28AM CDT
Regenerative medicine company Harvard Bioscience Inc (NasdaqGM:HBIO) revealed on Monday the appointment of Yoav Sibony to the newly created position of vice president of its Global Sales.
Harvard Bioscience Appoints Yoav Sibony as VP Global Sales
GlobeNewswire - Mon Oct 21, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that it has hired Yoav Sibony, a veteran sales manager, as Harvard Bioscience's Vice President of Global Sales, a newly created position, effective October 21.
HBIO Announces Details of Approved Spin-Off of Harvard Apparatus Regenerative Technology, Inc.
GlobeNewswire - Wed Oct 16, 6:10AM CDT
The Board of Directors of Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, has approved the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART.
Harvard Bioscience Names Robert E. Gagnon as Chief Financial Officer
GlobeNewswire - Wed Oct 16, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, has hired Robert E. Gagnon, a veteran financial executive, as Harvard Bioscience's Chief Financial Officer, effective as of the date of HBIO's planned spin-off of Harvard Apparatus Regenerative Technology, Inc., or HART, which is anticipated to be November 1, 2013, or the Distribution Date. From October 23, 2013 until the Distribution Date, Mr. Gagnon will initially serve as HBIO's Executive Vice President - Finance.
Harvard Bioscience Names Ronald Aplin to Vice President Global Operations and Quality
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately. This is a newly created position.
Nasdaq stocks posting largest volume increases
AP - Mon Mar 03, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Harvard Bioscience Reports Fourth Quarter and Year-End 2013 Results
GlobeNewswire - Thu Feb 27, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of specialized products to advance life science research, today reported financial highlights for the fourth quarter and full year ended December 31, 2013.
Harvard Bioscience Schedules Fourth Quarter and Year-End 2013 Conference Call for February 27, 2014 at 11:00 AM ET
GlobeNewswire - Fri Feb 14, 6:30AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, will announce results for its fourth quarter and year ended December 31, 2013 before market trading hours on Thursday, February 27, 2014. A conference call to discuss the company's fourth quarter and year-end financial results is scheduled for that same day at 11:00 AM ET.
Harvard Bioscience Realigns Global Operations to Create Organizational Efficiencies and Better Position It for Growth
GlobeNewswire - Wed Dec 04, 6:00AM CST
-Reallocating Resources to Higher-Growth Areas-
Upgrade Alert for Harvard Bioscience (HBIO)
Comtex SmarTrend(R) - Wed Nov 27, 7:04AM CST
Harvard Bioscience (NASDAQ:HBIO) was upgraded from Neutral to Buy at Sidoti today. The stock closed yesterday at $4.47 on volume of 393,000 shares, above average daily volume of 202,000. In the past 52 weeks, Harvard Bioscience share prices have been bracketed by a low of $3.45 and a high of $6.26 and closed yesterday at $4.47, 30% above that low price. The 200-day and 50-day moving averages have moved 0.29% lower and 1.21% lower over the past week, respectively.
Harvard Bioscience Announces Inducement Grants to Recently Hired Executives
GlobeNewswire - Mon Nov 18, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has granted the inducement stock option grants it was obligated to grant to its recently hired executives as follows:
Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology
GlobeNewswire - Wed Nov 13, 10:29AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, announced the allocation of tax basis resulting from the tax-free spin-off of Harvard Apparatus Regenerative Technology, Inc. Based on the relative fair market values of the respective companies on November 1, 2013, the first day of trading after distribution, 23.63 percent of a stockholder`s pre-distribution tax basis in Harvard Bioscience common stock should be allocated to the shares of common stock in Harvard Apparatus Regenerative Technology received pursuant to the distribution described in the Information Statement of Harvard Apparatus Regenerative Technology dated October 17, 2013.
Kellogg and BlackBerry are big market movers
AP - Mon Nov 04, 3:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Harvard Bioscience completes HART unit spinoff
AP - Mon Nov 04, 9:49AM CST
NEW YORK (AP) — Medical instruments maker Harvard Bioscience said Monday the spinoff of its Harvard Apparatus Regenerative Technology unit is complete.
Jeffrey A. Duchemin Appointed to Additional Roles of President and Director of Harvard Bioscience
GlobeNewswire - Mon Nov 04, 6:15AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that its Chief Executive Officer, Jeffrey A. Duchemin, has been appointed by the Board of Directors to the additional positions of President and Director, effective immediately. He replaces David Green, who has become President at Harvard Apparatus Regenerative Technology, Inc. (HART), which was spun off from HBIO on November 1, 2013. Mr. Green will remain on the Board of Directors of Harvard Bioscience.
Harvard Bioscience Becomes Pure-Play Developer, Manufacturer and Marketer of Tools for Life Science Research
GlobeNewswire - Mon Nov 04, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO) became a pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research on November 1, 2013. This development resulted as the previously announced spin-off of its former wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, or HART, was completed as of 12:01 a.m. on November 1, 2013.
Harvard Bioscience Reports Third Quarter 2013 Results
GlobeNewswire - Thu Oct 31, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and nine months ended September 30, 2013.
Harvard Bioscience Appoints Yong Sun as VP Strategic Marketing and Business Development
GlobeNewswire - Mon Oct 28, 6:00AM CDT
Nearly 20 Years Marketing Experience to Bolster Company's Future Expansion Into Asia and Emerging Markets
Five-Year Follow-Up of World's First Regenerated Trachea Transplant Published in The Lancet
GlobeNewswire - Wed Oct 23, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) and Harvard Apparatus Regenerative Technology (Nasdaq:HARTV) jointly announce that five years after a 30-year-old woman was implanted with the world's first tissue-engineered trachea grown in a bioreactor she lives complication-free, according to an article published October 23 in The Lancet.
Harvard Bioscience, Inc. Schedules Third Quarter 2013 Conference Call for October 31, 2013 at 11:00 AM ET
GlobeNewswire - Tue Oct 22, 2:40PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, will announce results for its third quarter ended September 30, 2013 before market trading hours on Thursday, October 31, 2013. A conference call to discuss the company's third quarter financial results is scheduled for that same day at 11:00 AM ET.
Harvard Bioscience Inc elects Yoav Sibony as VP its Global Sales
M2 - Mon Oct 21, 7:28AM CDT
Regenerative medicine company Harvard Bioscience Inc (NasdaqGM:HBIO) revealed on Monday the appointment of Yoav Sibony to the newly created position of vice president of its Global Sales.
Harvard Bioscience Appoints Yoav Sibony as VP Global Sales
GlobeNewswire - Mon Oct 21, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that it has hired Yoav Sibony, a veteran sales manager, as Harvard Bioscience's Vice President of Global Sales, a newly created position, effective October 21.
HBIO Announces Details of Approved Spin-Off of Harvard Apparatus Regenerative Technology, Inc.
GlobeNewswire - Wed Oct 16, 6:10AM CDT
The Board of Directors of Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, has approved the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART.
Harvard Bioscience Names Robert E. Gagnon as Chief Financial Officer
GlobeNewswire - Wed Oct 16, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, has hired Robert E. Gagnon, a veteran financial executive, as Harvard Bioscience's Chief Financial Officer, effective as of the date of HBIO's planned spin-off of Harvard Apparatus Regenerative Technology, Inc., or HART, which is anticipated to be November 1, 2013, or the Distribution Date. From October 23, 2013 until the Distribution Date, Mr. Gagnon will initially serve as HBIO's Executive Vice President - Finance.
